Streetbeat News

Products Services

DIS

FUBO

VERS

WBD

FuboTV's lawsuit against Disney, Fox, and Warner Bros. over a new sports-streaming service is set for trial in October 2025. The trial could delay the launch of the service, Venu Sports, which was planned for August 2023. The lawsuit is part of broader legal disputes over sports streaming rights.

Portfolio Pulse from Nabaparna Bhattacharya

September 13, 2024 | 2:18 pm

COHR

Coherent shares rise following a $2.45 million contract award for Phase 3 of its IARPA resilience program, focusing on high-energy rechargeable lithium-sulfur batteries.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 2:16 pm

PDD

Temu, a company potentially linked to PDD Holdings, states that its growth is not reliant on the de minimis policy, despite the Biden administration's move to curb low-value shipments. Temu is reviewing new rule proposals and remains committed to consumer value.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 2:09 pm

CCCC

C4 Therapeutics presented promising Phase 1 trial data for CFT1946, a treatment for BRAF V600 mutant solid tumors, at the ESMO Congress 2024. The drug showed good tolerance, no dose-limiting toxicities, and early anti-tumor activity, with further data expected in 2025.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 2:05 pm

AGEN

Botensilimab and Balstilimab have shown promising clinical responses in treating refractory sarcomas, as presented at ESMO 2024. The combination demonstrates broad and durable activity in advanced sarcoma patients.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 2:04 pm

PRLD

Prelude Therapeutics' SMARCA2 degrader, PRT3789, shows promising initial clinical activity and safety in a Phase 1 trial, particularly in patients with SMARCA4-mutated NSCLC and esophageal cancer. The drug was well-tolerated with no serious adverse events. An investor call is scheduled for September 13, 2024.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 2:03 pm

AZN

AstraZeneca and Daiichi Sankyo's drug ENHERTU shows promising results in treating HER2 positive metastatic breast cancer with brain metastases, achieving a 61.6% progression-free survival rate at one year in the DESTINY-Breast12 trial.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 2:03 pm

NUVL

Nuvalent has published a detailed study on their ALK-selective inhibitor, NVL-655, showcasing its preclinical activity and preliminary clinical case studies. This development is significant for the company's cancer treatment pipeline.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 2:00 pm

NUVL

Nuvalent, Inc. (NASDAQ:NUVL) announced a publication in Cancer Discovery detailing the design and preclinical activity of their ALK-selective inhibitor NVL-655. This drug is currently in Phase 1/2 trials for ALK-positive NSCLC and other tumors.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 1:56 pm

HISEF

Hisense Home Appliance's profit rose 34.6% in the first half of the year, driven by strong overseas growth, particularly in the Americas and Europe. Investment banks are optimistic about the company's potential, rating it a 'buy' due to its successful international expansion.

Portfolio Pulse from The Bamboo Works

September 13, 2024 | 1:48 pm